Our Approach
Targeted Therapeutic Intervention at the Interface of the Neurosensory and Immune Systems
We apply state-of-the-art medicinal chemistry and biological tools to develop targeted small molecule therapeutics that hold potential to become novel, highly differentiated treatment options for a broad range of diseases. Our initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs.
Our Therapeutic Programs
We are a clinical-stage company developing a pipeline of first-in-class, oral therapeutics targeting novel pathways along the neurosensory-inflammatory axis. Our product candidates are designed to address a broad range of disorders involving neurogenic inflammation – including chronic urticaria (hives), atopic dermatitis, and asthma – as well as severe forms of pruritus (chronic itchy skin).
Our lead programs include EP262 and EP547. We are currently evaluating EP262 in chronic urticaria and other mast cell mediated disorders and EP547 in cholestatic pruritus.
For Patients
Escient strives to discover and develop novel, life-changing medicines for patients. We are committed to advancing innovative solutions for some of the most challenging, underserved disorders worldwide, where current treatments are either insufficient or nonexistent.
Press Releases
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Read MoreThe Essence of Escient
At Escient, we are passionate about making a positive difference in the lives of patients by applying cutting-edge science. We foster a culture of innovation, collaboration, transparency, mutual respect, and integrity. We view ourselves as pioneers and value that spirit and creativity in every one of our employees.
